MannKind Corp. (MNKD)

[Phaeton]

According to Jason Karp at Tourbillion the sky is falling on MannKind. Oh my my. I better put my head between my legs and kiss my ? Goodbye.

MannKind, which makes inhalable insulin that Tourbillon believes will struggle commercially, fell 46 percent in the third quarter. This helped produce a 71 percent return for New York-based Tourbillon, Karp wrote in a letter to investors, a copy of which was obtained by Bloomberg News. The firm, which manages $1.3 billion, said the stock should fall to $1 from about $6.




Oh my the sky is falling on Mannkind. I guess the fact they have a great partner like Sanofi who is going to roll out the Launch details on November 20,2014 means nothing to Jason Karp of Tourbillion.

http://en.sanofi.com/investors/events/corporate/2014/2014-11-20_IR_Seminar_NMD.aspx
Sanofi will hold an IR Thematic Seminar on New Medicines at the Genzyme Headquarters in Cambridge, MA.


A live video webcast of the seminar will be available at
2:30 pm CET / 1:30 pm GMT / 8:30 am EST.

The event will be the first in a new series of events focusing on late-stage pipeline assets.

The agenda will consist of several deep dive sessions on new medicines and vaccines that we expect to launch in 2015, such as alirocumab, Dengue vaccine, Toujeo® and Afrezza®. A high level update on the next wave of innovative medicines and vaccines will also be provided.

The presentations will be followed by a Q&A session